drugset / Trial / NCT04088721
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
Phase 1/2
Completed
48 enrolled
Advagene Biopharma Co. Ltd.
Clinipace Worldwide · collabTaipei Medical University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.
Timeline
- Start
- 2019-03-26
- Primary completion
- 2020-07-30
- Completion
- 2020-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AD17002 | Protein / enzyme biologic | 20 ug | Intranasal |
| Subject | AD17002 | Protein / enzyme biologic | 40 ug | Intranasal |
| Subject | AD17002 | Protein / enzyme biologic | 60 ug | Intranasal |